The First Gallium-68 PET-CT Scan in Romania’s Public Healthcare System: A New Milestone in Oncology Diagnostics
Romania’s nuclear medicine sector has reached an important milestone with the successful completion of the country’s first Gallium-68 (Ga-68) PET-CT scan in a public hospital. Performed at the “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology in Bucharest, this examination marks a significant step forward in expanding patient access to advanced molecular imaging technologies widely used internationally in the management of selected cancers.
For patients with prostate cancer, as well as those diagnosed with neuroendocrine tumors, this imaging technique can provide essential information about the location and extent of disease, helping multidisciplinary teams make more informed treatment decisions.
Why Is This Milestone So Important?
In oncology, accurate diagnosis is the foundation of personalized treatment. The more precise the information available about a patient’s disease, the better clinicians can tailor therapeutic strategies to individual needs.
Gallium-68 PET-CT is one of the technologies that has transformed the evaluation of certain cancers. Unlike conventional imaging techniques, it provides molecular-level information and can identify lesions that may not always be visible on computed tomography (CT) or magnetic resonance imaging (MRI), depending on the clinical setting.
This level of precision is particularly valuable both during the initial staging of cancer and throughout patient follow-up after treatment.
What Is Gallium-68?
Gallium-68 is a radioisotope used in PET imaging. In prostate cancer, it is combined with PSMA (Prostate-Specific Membrane Antigen), a molecule that binds to prostate cancer cells, allowing them to be visualized during the scan.
The result is a highly detailed image that complements information obtained through other imaging modalities and may support the development of a treatment plan tailored to each patient’s clinical profile.
Gallium-68 has become widely adopted in medical centers around the world and is considered a reference standard for PET imaging in several oncological indications.
What Does This Technology Mean for Patients?
Prostate cancer is among the most commonly diagnosed cancers in Romanian men. In this context, access to advanced molecular imaging can provide significant benefits for both diagnosis and disease monitoring.
Among the potential advantages of Gallium-68 PET-CT are:
- the ability to detect cancer cells at very low prostate-specific antigen (PSA) levels, enabling a more accurate assessment of disease extent;
- detection of recurrence in selected clinical situations, including cases where other imaging modalities may have limitations;
- supporting treatment selection based on each patient’s individual characteristics;
- integrating molecular imaging findings into a personalized therapeutic approach.
For many patients, the availability of this technology in Romania may translate into faster access to advanced diagnostic services and reduce the need to seek such investigations abroad.
Advancing Nuclear Medicine in Romania
The introduction of Gallium-68 PET-CT into Romania’s public healthcare system reflects the continued development of nuclear medicine and the joint efforts of healthcare institutions and industry partners to implement innovative medical technologies.
Torus Pharma is committed to advancing and expanding access to nuclear medicine by supporting the introduction of innovative diagnostic and therapeutic solutions for oncology patients. This commitment builds on the company’s previous initiatives in nuclear medicine-based therapies and reflects its long-term objective of facilitating access to internationally recognized medical technologies.
A Step Forward for Romanian Oncology
The first Gallium-68 PET-CT scan performed in a public hospital represents more than a medical first. It demonstrates that advanced nuclear medicine technologies are becoming increasingly accessible in Romania, providing physicians with additional tools for accurate diagnosis and helping patients benefit from modern, precision-based healthcare.
As these technologies continue to be integrated into clinical practice, Romania’s healthcare system moves closer to delivering more precise diagnostics and increasingly personalized cancer care.
Learn More
For additional information about this medical milestone and the introduction of Gallium-68 PET-CT into Romania’s public healthcare system, we invite you to read the article published by Click Sănătate:
“Premieră în diagnosticarea și monitorizarea afecțiunilor oncologice în sistemul de stat”
Source: https://clicksanatate.ro/actualitate/premiera-in-diagnosticarea-si-monitorizarea-2543302.html
